Bloomberg Law
Feb. 24, 2023, 2:15 PM

Pfizer’s Paxlovid to Face FDA Advisory Panel Meeting on March 16

Bre Bradham
Bre Bradham
Bloomberg News
Jeremy R. Cooke
Jeremy R. Cooke
Bloomberg News

Pfizer Inc.’s Covid-19 therapy Paxlovid will face a panel of FDA advisers on March 16 as the drugmaker seeks full approval for the pill, according to an FDA filing.

  • The meeting is to discuss the company’s new drug application for Paxlovid, for the proposed indication of treating mild-to-moderate Covid-19 for adults who are at high risk of having a more severe form of the disease, including hospitalization or death
  • Paxlovid is currently available under an emergency-use authorization

To contact the reporters on this story:
Bre Bradham in New York at;
Jeremy R. Cooke in Mount Pleasant, SC ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.